DK1480985T3 - Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer - Google Patents

Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer

Info

Publication number: DK1480985T3
Authority: DK; Denmark
Prior art keywords: clopidogrel; salt; preparation; pharmaceutical formulations; benzenesulfonic acid
Prior art date: 2003-02-13

Application number

DK04700011T

Other languages

English (en)

Inventor

Karlheinz Doser

Klaus Glaenzer

Original Assignee

Helm Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-13

Filing date

2004-02-13

Publication date

2005-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32797377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1480985(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-02-13 Application filed by Helm Ag filed Critical Helm Ag

2005-06-06 Application granted granted Critical

2005-06-06 Publication of DK1480985T3 publication Critical patent/DK1480985T3/da

Links

GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title abstract 7
239000005552 B01AC04 - Clopidogrel Substances 0.000 title abstract 6
229960003009 clopidogrel Drugs 0.000 title abstract 6
150000003839 salts Chemical class 0.000 title abstract 3
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 title 1
229940092714 benzenesulfonic acid Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract 2
239000003463 adsorbent Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
238000001556 precipitation Methods 0.000 abstract 2
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 abstract 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 abstract 1
239000003146 anticoagulant agent Substances 0.000 abstract 1
229940127219 anticoagulant drug Drugs 0.000 abstract 1
229940127218 antiplatelet drug Drugs 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Steroid Compounds (AREA)

DK04700011T 2003-02-13 2004-02-13 Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer DK1480985T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10305984A DE10305984A1 (de)	2003-02-13	2003-02-13	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
PCT/EP2004/001369 WO2004072084A1 (de)	2003-02-13	2004-02-13	Salz der benzolsulfonsäure mit clopidogrel und dessen verwendung zur herstellung pharmazeutischer formulierungen

Publications (1)

Publication Number	Publication Date
DK1480985T3 true DK1480985T3 (da)	2005-06-06

Family

ID=32797377

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04710847T DK1592694T3 (da)	2003-02-13	2004-02-13	Partikler med aktivt stof med clopidogrel eller et farmaceutisk forligeligt salt deraf
DK04700011T DK1480985T3 (da)	2003-02-13	2004-02-13	Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK04710847T DK1592694T3 (da)	2003-02-13	2004-02-13	Partikler med aktivt stof med clopidogrel eller et farmaceutisk forligeligt salt deraf

Country Status (15)

Country	Link
US (2)	US20050256152A1 (da)
EP (4)	EP1592694B1 (da)
JP (1)	JP2006515338A (da)
KR (3)	KR20050008692A (da)
AT (3)	ATE290535T1 (da)
BR (1)	BRPI0407430A (da)
CA (2)	CA2481848C (da)
DE (5)	DE10305984A1 (da)
DK (2)	DK1592694T3 (da)
ES (2)	ES2236679T3 (da)
MX (1)	MXPA05007557A (da)
PL (2)	PL378572A1 (da)
PT (2)	PT1480985E (da)
SI (2)	SI1480985T1 (da)
WO (2)	WO2004072085A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002217464B2 (en) *	2000-12-25	2004-12-16	Daiichi Sankyo Company, Limited	Medicinal compositions containing aspirin
DE10305984A1 (de)	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
ES2531088T3 (es) *	2003-04-25	2015-03-10	Cadila Healthcare Ltd	Sales de clopidogrel y procedimiento de preparación
ATE455778T1 (de) *	2003-11-03	2010-02-15	Cadila Healthcare Ltd	Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
CN1922188A (zh) *	2004-02-24	2007-02-28	齐格弗里德通用国际股份公司	氯吡格雷之药学可接受的盐
KR100563455B1 (ko) *	2004-04-09	2006-03-23	한미약품 주식회사	결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
CA2562532C (en) *	2004-04-09	2010-02-16	Hanmi Pharm. Co., Ltd.	Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
UA83919C2 (en) *	2004-04-20	2008-08-26	Санофи Авентис	Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide
ZA200608035B (en) *	2004-04-20	2008-07-30	Sanofi Aventis	Clopidogrel salt and polymorphic forms thereof
WO2006044548A2 (en) *	2004-10-14	2006-04-27	Dr. Reddy's Laboratories Ltd.	Clopidogrel compositions
TWI347942B (en) *	2005-06-22	2011-09-01	Lundbeck & Co As H	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
ES2391410T3 (es) *	2005-09-05	2012-11-26	Cadila Healthcare Limited	Procedimientos para la preparación de diferentes formas de (s)-(+)-clopidogrel besilato
WO2007054968A2 (en) *	2005-09-20	2007-05-18	Torrent Pahrmaceuticals Limited	Novel pharmaceutical compositions of clopidogrel mesylate
US20080226579A1 (en) *	2005-09-21	2008-09-18	Chong Kun Dang Pharmaceutical Corp.	Novel Resinate Complex of S-Clopidogrel and Production Method Thereof
KR100791687B1 (ko) *	2006-02-27	2008-01-03	채종근	결정성 클로피도그렐 설포살리실산 염을 포함하는 제제
KR100945062B1 (ko) *	2006-03-22	2010-03-05	한미약품 주식회사	클로피도그렐 1,5-나프탈렌디술폰산염 및 이의 수화물의제조방법
KR100834967B1 (ko) *	2006-08-11	2008-06-03	에스케이케미칼주식회사	여액의 라세미화 반응에 의한 ｓ-(＋)-클로피도그렐의고수율 제조방법
EP1900358A1 (en) *	2006-09-16	2008-03-19	Cimex Pharma AG	Pharmaceutical formulations comprising clopidogrel
ATE498626T1 (de) *	2006-09-25	2011-03-15	Adamed Sp Zoo	Neues clopidogrel-salz und seine kristallinen formen
CN100400035C (zh) *	2006-10-18	2008-07-09	深圳信立泰药业股份有限公司	氯吡格雷硫酸盐的固体制剂及其制备方法
WO2008060934A2 (en) *	2006-11-14	2008-05-22	Acusphere, Inc.	Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
ATE513834T1 (de)	2006-11-24	2011-07-15	Cadila Healthcare Ltd	Verfahren zur herstellung von (s)-(+)- clopidogrelbase und deren salzen
WO2008081473A2 (en) *	2006-12-29	2008-07-10	Cadila Healthcare Limited	Process for preparing clopidogrel
JP5681485B2 (ja)	2007-04-27	2015-03-11	サイデックス・ファーマシューティカルズ・インコーポレイテッド	クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
KR20090022616A (ko) *	2007-08-31	2009-03-04	한올제약주식회사	베실산클로피도그렐 함유 경구투여용 약제
KR100920932B1 (ko) *	2007-12-05	2009-10-20	한림제약(주)	결정형의 클로피도그렐 벤젠술폰산염의 제조방법
EP2107061A1 (en)	2008-04-02	2009-10-07	Krka Tovarna Zdravil, D.D., Novo Mesto	Process for the preparation of optically enriched clopidogrel
CA2761455C (en)	2009-05-13	2018-06-12	Cydex Pharmaceuticals, Inc.	Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
WO2012123958A1 (en)	2011-02-14	2012-09-20	Cadila Healthcare Limited	Highly pure salts of clopidogrel free of genotoxic impurities
CN102285996A (zh) *	2011-03-30	2011-12-21	天津红日药业股份有限公司	一种苯磺酸氯吡格雷晶型ⅱ及其制备方法和用途
CN102199161B (zh) *	2011-03-30	2013-07-03	天津红日药业股份有限公司	一种苯磺酸氯吡格雷晶型ⅰ及其制备方法和用途
HUP1400294A2 (hu)	2014-06-13	2015-12-28	Skillpharm Kft	Clopidogrel új alkalmazása
CN104193762B (zh) *	2014-08-04	2017-02-15	浙江车头制药股份有限公司	一种制备苯磺酸氯吡格雷晶型ⅲ的方法
CN115327005B (zh) *	2022-08-12	2024-01-26	成都施贝康生物医药科技有限公司	一种氧化氯吡格雷有关物质的检测方法
CN118141928A (zh) *	2024-03-11	2024-06-07	上海交通大学	P2ry12抑制剂在制备治疗肥胖症、超重和代谢综合征疾病的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2530247B1 (fr) *	1982-07-13	1986-05-16	Sanofi Sa	Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2623810B2 (fr) *	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2740686B1 (fr) *	1995-11-03	1998-01-16	Sanofi Sa	Formulation pharmaceutique lyophilisee stable
US6509348B1 (en) *	1998-11-03	2003-01-21	Bristol-Myers Squibb Company	Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
AU3192700A (en) *	1999-03-17	2000-10-04	Daiichi Pharmaceutical Co., Ltd.	Medicinal compositions
DE10109763A1 (de) *	2001-02-28	2002-09-05	Gruenenthal Gmbh	Pharmazeutische Salze
DE10153078A1 (de) *	2001-10-30	2003-05-22	Degussa	Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
IL166593A0 (en) *	2002-08-02	2006-01-15		Racemization and enantiomer separation of clopidogrel
DE10305984A1 (de)	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
ES2531088T3 (es) *	2003-04-25	2015-03-10	Cadila Healthcare Ltd	Sales de clopidogrel y procedimiento de preparación

2003
- 2003-02-13 DE DE10305984A patent/DE10305984A1/de not_active Withdrawn
2004
- 2004-02-13 KR KR10-2004-7016868A patent/KR20050008692A/ko not_active Ceased
- 2004-02-13 EP EP04710847A patent/EP1592694B1/de not_active Revoked
- 2004-02-13 KR KR1020047016562A patent/KR100805176B1/ko not_active Expired - Lifetime
- 2004-02-13 CA CA002481848A patent/CA2481848C/en not_active Expired - Fee Related
- 2004-02-13 PT PT04700011T patent/PT1480985E/pt unknown
- 2004-02-13 PT PT04710847T patent/PT1592694E/pt unknown
- 2004-02-13 DK DK04710847T patent/DK1592694T3/da active
- 2004-02-13 AT AT04700011T patent/ATE290535T1/de not_active IP Right Cessation
- 2004-02-13 PL PL378572A patent/PL378572A1/pl not_active Application Discontinuation
- 2004-02-13 PL PL04373512A patent/PL373512A1/xx not_active Application Discontinuation
- 2004-02-13 DE DE202004021399U patent/DE202004021399U1/de not_active Expired - Lifetime
- 2004-02-13 AT AT05009790T patent/ATE512153T1/de active
- 2004-02-13 AT AT04710847T patent/ATE361305T1/de active
- 2004-02-13 BR BR0407430-0A patent/BRPI0407430A/pt not_active IP Right Cessation
- 2004-02-13 SI SI200430001T patent/SI1480985T1/xx unknown
- 2004-02-13 US US10/510,578 patent/US20050256152A1/en not_active Abandoned
- 2004-02-13 DK DK04700011T patent/DK1480985T3/da active
- 2004-02-13 WO PCT/EP2004/001370 patent/WO2004072085A2/de not_active Ceased
- 2004-02-13 CA CA002468089A patent/CA2468089A1/en not_active Abandoned
- 2004-02-13 ES ES04700011T patent/ES2236679T3/es not_active Expired - Lifetime
- 2004-02-13 WO PCT/EP2004/001369 patent/WO2004072084A1/de not_active Ceased
- 2004-02-13 EP EP05009790A patent/EP1595884B1/de not_active Expired - Lifetime
- 2004-02-13 DE DE502004003680T patent/DE502004003680D1/de not_active Expired - Lifetime
- 2004-02-13 SI SI200430313T patent/SI1592694T1/sl unknown
- 2004-02-13 JP JP2006500030A patent/JP2006515338A/ja active Pending
- 2004-02-13 ES ES04710847T patent/ES2282848T3/es not_active Expired - Lifetime
- 2004-02-13 DE DE502004000002T patent/DE502004000002D1/de not_active Revoked
- 2004-02-13 DE DE202004021381U patent/DE202004021381U1/de not_active Ceased
- 2004-02-13 EP EP04700011A patent/EP1480985B1/de not_active Revoked
- 2004-02-13 EP EP05009789A patent/EP1586575A3/de not_active Withdrawn
- 2004-02-13 MX MXPA05007557A patent/MXPA05007557A/es active IP Right Grant
- 2004-02-13 KR KR1020067018596A patent/KR20060103472A/ko not_active Ceased
2005
- 2005-04-25 US US11/113,467 patent/US20050203122A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20060103472A (ko)	2006-09-29
US20050203122A1 (en)	2005-09-15
EP1595884B1 (de)	2011-06-08
DE202004021399U1 (de)	2007-11-22
SI1480985T1 (en)	2005-06-30
PT1592694E (pt)	2007-06-14
CA2481848C (en)	2006-10-10
KR100805176B1 (ko)	2008-02-21
CA2468089A1 (en)	2004-08-13
PL378572A1 (pl)	2006-05-02
WO2004072085A3 (de)	2004-10-28
ATE290535T1 (de)	2005-03-15
ATE512153T1 (de)	2011-06-15
KR20050008692A (ko)	2005-01-21
SI1592694T1 (sl)	2007-08-31
BRPI0407430A (pt)	2006-01-24
DE502004003680D1 (de)	2007-06-14
DE10305984A1 (de)	2004-09-02
ES2282848T3 (es)	2007-10-16
KR20040101503A (ko)	2004-12-02
ATE361305T1 (de)	2007-05-15
DK1592694T3 (da)	2007-08-13
JP2006515338A (ja)	2006-05-25
DE202004021381U1 (de)	2007-11-15
WO2004072085A2 (de)	2004-08-26
EP1592694B1 (de)	2007-05-02
WO2004072084A1 (de)	2004-08-26
US20050256152A1 (en)	2005-11-17
PT1480985E (pt)	2005-05-31
EP1480985A1 (de)	2004-12-01
DE502004000002D1 (de)	2005-04-14
EP1595884A2 (de)	2005-11-16
PL373512A1 (en)	2005-09-05
EP1592694A2 (de)	2005-11-09
ES2236679T3 (es)	2005-07-16
CA2481848A1 (en)	2004-08-26
EP1595884A3 (de)	2006-09-06
EP1586575A2 (de)	2005-10-19
EP1480985B1 (de)	2005-03-09
EP1586575A3 (de)	2006-09-06
MXPA05007557A (es)	2005-11-17

Publication	Publication Date	Title
DK1480985T3 (da)	2005-06-06	Salt af benzensulfonsyre med clopidogrel og anvendelse af denne til fremstilling af farmaceutiske formuleringer
WO2008131149A3 (en)	2009-06-25	Crystal forms of saxagliptin and processes for preparing same
NO20071290L (no)	2007-05-29	Enantiomert rene aminoheteroarylforbindelser som protein kinase inhibitorer
JP2006516528A5 (da)	2007-03-08
WO2005097809A3 (en)	2006-02-16	Synthesis of boronic ester and acid compounds
WO2005063971A3 (en)	2005-12-15	Definitive endoderm
CA3159172A1 (en)	2021-06-10	Masp-2 inhibitors and methods of use
JP2005528466A5 (da)	2006-04-20
WO2006002348A3 (en)	2006-05-04	Solid and crystalline ibandronic acid
NO20076682L (no)	2008-03-05	Nye pyridinanaloger
BR9811527A (pt)	2000-08-22	Método para a produção de amÈnia
Budt et al.	1995	HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols
Glunz et al.	2013	Nonbenzamidine acylsulfonamide tissue factor–factor VIIa inhibitors
CN104628649A (zh)	2015-05-20	一种2-(α-羟基戊基)苯甲酰胺衍生物及其制备方法、制剂与应用
ATE541037T1 (de)	2012-01-15	Verfahren zur trennung und reinigung von nukleinsäure
FI20041056A7 (fi)	2006-02-05	Menetelmä orgaanisten ja epäorgaanisten aineosien talteenottamiseksi jätevirrasta
ATE491686T1 (de)	2011-01-15	Amlodipin-gentisat und verfahren zu dessen herstellung
MX2007006018A (es)	2007-06-07	Suspension farmaceutica oral novedosa de cristal de cefdinir.
PL1960521T3 (pl)	2012-01-31	Sposób i zestaw do rozdzielania, oczyszczania i odzyskiwania długo- i krótkołańcuchowych kwasów nukleinowych
WO2006074919A3 (de)	2007-02-01	3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG
WO2004026261A3 (en)	2004-08-26	Composition containing ribavirin and use thereof
AR050004A1 (es)	2006-09-20	Proceso mejorado para la fabricacion de mirtazapina
AR054128A1 (es)	2007-06-06	Derivados del acido 6,7-dihidro-5h-imidazo(1, 2- a)imidazol-3-sulfonico
WO2003039482A3 (en)	2003-11-20	Polymorphs of fexofenadine base
NO20061290L (no)	2006-05-22	Nye forbindelser